Saccharomyces boulardii is a non-pathogenic yeast strain that has been used for treatment and prevention of diarrhea. Saccharomyces boulardii is classified as a "probiotic," or a microorganism that when ingested may have a positive influence on the host's health. Probiotics may exert their effects on the gastrointestinal system directly, or may modulate the immune system in a larger scope.
Human studies indicate Saccharomyces boulardii may prevent antibiotic-associated diarrhea, Clostridium difficile diarrhea in combination with antibiotic therapy, diarrhea associated with tube feeds, and acute childhood diarrhea. Promising initial studies have shown that Saccharomyces boulardii may be beneficial in treating diarrhea associated with HIV.
The German Commission E has approved the use of Saccharomyces boulardii for symptomatic treatment of acute diarrhea, prophylactic and symptomatic treatment of diarrhea during travel, treatment of diarrhea occurring while tube feeding, use as an adjuvant for chronic acne, for a dietary supplementation, and for a source of B vitamins and protein.
Brewer's yeast, Florastor®, Florastor® Kids, Hansen CBS 5926, Lactobacillus, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus gasseri, Lactobacillus GG, Lactobacillus plantarum, Perenterol®, probiotic, S. boulardii, Saccharomyces cerevisiae, Saccharomyces salivarius, Saccharomyces thermophilus, Saccharomycetaceae (family), Ultra-Levure®, yeast.
Note: There is debate as to whether Saccharomyces boulardii is a subspecies of Saccharomyces cerevisiae or a separate entity. Traditional techniques cannot distinguish the two, but manufacturers of Saccharomyces boulardii claim that the two yeasts are separate species.
These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider.
Diarrhea (antibiotic associated)
There is good evidence that concurrent use of
Diarrhea in children
Several trials suggest efficacy of
Evidence from one clinical trial supports improvement of symptoms and in patients with amebiasis treated with
Evidence supports mild improvement of symptoms and quality of life in patients with Crohn's disease who use
Diarrhea (Clostridium difficile)
With the introduction of broad-spectrum antibiotics into clinical practice,
Diarrhea (HIV associated)
While only small studies have been performed, treatment with
Diarrhea (prevention during tube feeding)
Preliminary evidence supports the use of
Although evidence supports the use of
Irritable bowel syndrome (IBS)
One clinical trial exists to support treatment with
Nutritional support (premature infants)
One clinical trial exists investigating the addition of